Peptide hydrogels for delivery of immunosuppressive drugs and uses thereof
AssigneesThe Johns Hopkins University, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsJoel P. SCHNEIDER, Poulami MAJUMDER, Giorgio RAIMONDI
Life of this patent
Estimating the term…
Abstract
Compositions that include a cationic peptide hydrogel and an immunosuppressive small molecule drug are described. The small molecule drug is crystallized and dispersed in the peptide hydrogel to allow for slow release of the drug. Methods of inhibiting allograft rejection and treating autoimmune-mediated organ damage by local administration of the peptide hydrogel compositions are described.
Claims25
A composition comprising a cationic amphiphilic peptide hydrogel and crystallized tofacitinib dispersed within the peptide hydrogel, wherein the amino acid sequence of the peptide comprises or consists of VKVKVKVKVDPPTKVEVKVKV (SEQ ID NO:
- 33), VLTKVKTKVDPPTKVEVKVLV (SEQ ID NO:
- 30) or VKVKVKVKVDPPTKVKVKVKV (SEQ ID NO:
- 31) and wherein the peptide is acetylated at the N-terminus and amidated at the C-terminus.
A composition comprising a cationic amphiphilic peptide hydrogel and a crystallized immunosuppressive small molecule drug dispersed within the peptide hydrogel, wherein the amino acid sequence of the peptide comprises or consists of the amino acid sequence set forth as:
- (XZ)nX-[DPP, DPG,
- or
- NG]-X(ZX)n
- and wherein
- each X is individually selected from V, I, L, M, T, F, W, and Y;
- each Z is individually selected from any amino acid;
- n is from 3 to 5;
- and
- the peptide has a net positive charge at neutral pH.
(canceled)
(canceled)
(canceled)
(canceled)
-26. (canceled)
Dependencies are inferred from the claim text.